A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in
patients, based on slow onset of action and an inability to provide 24-hour gastric-acid
suppression. Clinical data on AH234844 demonstrates a rapid onset of action, high potency,
and prolonged duration of effect. The present study endeavors, in part, to compare
lavoltidine to two GERD drugs, NEXIUM and ranitidine.